An observational study in Emergency Medicine and Stroke Acute, sponsored by Izmir Katip Celebi University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Izmir Katip Celebi University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Ischemic Stroke with a site in Turkey — 12 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · Turkey.
Among the 54 studies in Ischemic Stroke with a site in Turkey, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 8 that started in 2026, is one of 16 observational ones, reaches primary completion later than 10 of the 15 other live ones, and was the 48th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →12 of the 54 studies in Ischemic Stroke with a site in Turkey are open now. Recruiting first, the newest first:
Ankara Etlik City Hospital · Sites in Turkey
Ages 45+
Fenerbahce University · Sites in Turkey
Ages 18–80
Fenerbahce University · Sites in Turkey
Ages 18–80
RapidPulse, Inc · Sites in Turkey, United States, France and 1 more country
Ages 18–85
Akdeniz University · Sites in Turkey
Ages 45+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 50 across the 37 interventional studies, 90 across the 16 observational. Of the 34 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 54 have an industry lead sponsor. The 10 most frequent:
Izmir Katip Celebi University is the lead sponsor of 198 studies on the registry; 39 are open to participants now.
Izmir Katip Celebi University has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
5 of the studies in Ischemic Stroke with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07453277Izmir Katip Celebi UniversityBlood-Based Molecular Clock Biomarkers Predict Acute Ischemic Stroke Onset: A Prospective Observational Study | 2027-03-01 |
| NCT07456956Fenerbahce UniversityHIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke | 2027-04-06 |
| NCT06029491RapidPulse, IncThrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions | 2027-06 |
| NCT06370182Anaconda Biomed S.L.Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter | 2027-08 |
| NCT07834333Ankara Etlik City HospitalEffectiveness of Theta Burst Stimulation For Upper and Lower Extremity Recovery in Stroke | 2027-08-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 54 studies in Ischemic Stroke with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute ischemic stroke (AIS) is a major cause of mortality and long-term neurological disability worldwide. The effectiveness of reperfusion therapies such as intravenous thrombolysis and mechanical thrombectomy is highly dependent on the time elapsed since symptom onset. However, in approximately 15-25% of patients, the exact onset time cannot be determined because symptoms begin during sleep (wake-up stroke) or the onset is otherwise unclear. This uncertainty often prevents patients from receiving time-dependent reperfusion treatments.
Currently, imaging-based approaches such as diffusion-weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch are used to estimate the biological stage of ischemia in patients with unknown onset time. However, advanced imaging techniques may not be available in all centers and interpretation may vary.
This study aims to evaluate the diagnostic performance of a multi-biomarker panel representing different biological components of ischemic brain injury, including glial, neuronal, axonal, cellular stress, and vascular responses. Blood samples obtained at admission will be analyzed for glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), serum neurofilament light chain (sNfL), phosphatidylethanolamine-binding protein 1 (PEBP1), and matrix metalloproteinase-9 (MMP-9).
The primary objective is to determine whether this biomarker panel can distinguish patients presenting within ≤4.5 hours from those presenting after >4.5 hours of symptom onset. Biomarker findings will be compared with imaging-based reference methods to explore the feasibility of a blood-based "molecular clock" approach for estimating stroke timing in patients with uncertain onset.
Acute ischemic stroke (AIS) is one of the leading causes of mortality and long-term neurological disability worldwide. The effectiveness of reperfusion therapies, including intravenous thrombolysis and mechanical thrombectomy, is highly dependent on the time elapsed since symptom onset. Determination of the symptom onset time is therefore a critical component of treatment eligibility. However, a substantial proportion of patients present with stroke symptoms of unknown onset, most commonly because the symptoms develop during sleep (wake-up stroke) or because the exact onset time cannot be reliably established. This uncertainty may prevent eligible patients from receiving time-dependent reperfusion therapies.
Current clinical decision-making in patients with uncertain onset time relies largely on imaging-based approaches that attempt to estimate the biological stage of ischemia. The diffusion-weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch concept is the most widely used method and is based on the hypothesis that tissue signal evolution reflects the duration of ischemia. Advanced perfusion imaging techniques have also been incorporated into clinical practice. However, these imaging methods require specialized equipment and expertise, may not be available in all centers, and their interpretation may vary between institutions. Consequently, there is increasing interest in identifying circulating biomarkers that can reflect the biological timing of ischemic injury.
Ischemic brain injury initiates a complex cascade of pathophysiological processes involving astroglial activation, neuronal membrane disruption, axonal injury, inflammatory signaling, cellular stress responses, and vascular dysfunction. These processes evolve dynamically over time and lead to the release of measurable molecular components into the systemic circulation. Biomarkers reflecting different cellular compartments of the neurovascular unit may therefore provide complementary information regarding the temporal evolution of ischemic injury.
Several candidate biomarkers have been identified that represent different biological aspects of this process. Glial fibrillary acidic protein (GFAP) is an astrocyte-specific structural protein that reflects astroglial injury and early glial activation following acute brain damage. Ubiquitin C-terminal hydrolase L1 (UCH-L1) is a neuron-specific cytoplasmic enzyme released after neuronal membrane disruption and has been proposed as an indicator of acute neuronal injury. Serum neurofilament light chain (sNfL) is a structural component of the axonal cytoskeleton and is considered a marker of axonal degeneration and structural neuronal damage. Phosphatidylethanolamine-binding protein 1 (PEBP1), also known as Raf kinase inhibitory protein, is involved in the regulation of cellular signaling pathways and stress responses and may reflect cellular adaptation to ischemic stress. Matrix metalloproteinase-9 (MMP-9) is associated with inflammatory activation, extracellular matrix degradation, and blood-brain barrier dysfunction during the evolution of ischemic brain injury.
The combined evaluation of biomarkers representing multiple biological layers of the neurovascular unit may provide a more comprehensive representation of the temporal dynamics of ischemic injury than single-marker approaches. A multi-biomarker strategy has the potential to capture different phases of the ischemic cascade, including glial activation, neuronal damage, axonal injury, cellular stress response, and vascular dysfunction.
The present study aims to investigate whether a multi-compartment biomarker panel can contribute to the estimation of the biological timing of acute ischemic stroke. By evaluating circulating biomarkers representing different components of the neurovascular unit, the study seeks to explore the feasibility of a blood-based molecular signature that reflects the temporal evolution of ischemic injury.
The findings of this study may contribute to the development of a biologically informed approach for estimating stroke timing and may support clinical decision-making in patients presenting with uncertain symptom onset, particularly in settings where advanced imaging techniques are not readily available.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
This study's planned enrollment of 80 is below the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Izmir Katip Celebi University is the lead sponsor of 198 studies on the registry; 39 are open to participants now.
Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with acute ischemic stroke whose onset time is unknown or who present with a wake-up stroke.
Serum/plasma samples obtained from venous blood samples taken during routine clinical practice in all patients will be analyzed for GFAP, UCH-L1, sNfL, PEBP1, and MMP-9 levels. Patients' demographic data, clinical characteristics, NIHSS scores, and magnetic resonance imaging (MRI) findings (particularly DWI-FLAIR mismatch status) will be recorded from the electronic patient record system. The performance of the multi-compartment molecular panel formed by the obtained biomarker levels in distinguishing the biological time window of acute ischemic stroke (≤4.5 hours vs. >4.5 hours) will be evaluated by comparing it with the imaging-based reference method.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACUTE STROKE PRESENTING TO THE EMERGENCY DEPARTMENT (WITNESSED STROKE, STROKE WITH KNOWN OCCURRENCE)
WAKE UP STROKE (Without Witnesses and Unknown Start Time)
Diagnostic performance of the multi-biomarker panel in identifying the biological time window of acute ischemic stroke (≤4.5 hours vs >4.5 hours from symptom onset)
The primary outcome will be the ability of the combined biomarker panel (GFAP, UCH-L1, sNfL, PEBP1, and MMP-9) measured from admission blood samples to discriminate patients presenting within ≤4.5 hours versus \>4.5 hours after symptom onset. Diagnostic performance will be evaluated using receiver operating characteristic (ROC) curve analysis and reported as area under the curve (AUC), sensitivity, specificity, and optimal cut-off values.
Time frame: At emergency department admission.
Diagnostic performance of individual biomarkers
The diagnostic accuracy of each biomarker (GFAP, UCH-L1, sNfL, PEBP1, and MMP-9) will be evaluated individually for distinguishing ≤4.5 hours versus \>4.5 hours from symptom onset using ROC curve analysis.
Time frame: At emergency department admission.
Association between biomarker levels and imaging-based reference methods
Circulating biomarker levels will be compared with imaging findings used to estimate stroke timing (e.g., DWI-FLAIR mismatch or other clinically available imaging parameters) to assess concordance between molecular and imaging-based indicators of ischemic timing.
Time frame: Baseline imaging obtained at hospital admission.
Incremental diagnostic value of the combined biomarker model
We will assess multivariable models that include the biomarker panel to see if analyzing the biomarkers together offers better diagnostic accuracy than looking at each biomarker separately.
Time frame: At emergency department admission.
Correlation between circulating biomarker levels and infarct volume on diffusion-weighted imaging (DWI)
The relationship between admission biomarker concentrations (GFAP, UCH-L1, sNfL, PEBP1, and MMP-9) and infarct volume measured on diffusion-weighted magnetic resonance imaging (DWI) will be evaluated to explore the association between molecular markers of ischemic injury and the extent of cerebral infarction. Correlation analyses will be performed to determine whether biomarker levels reflect infarct burden.
Time frame: Baseline imaging obtained within the initial diagnostic evaluation after hospital admission.
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 12 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Izmir Katip Celebi University →